vaccin
develop
long
first
foremost
approach
control
viral
diseas
saminathan
et
al
howev
develop
first
human
antivir
drug
idoxuridin
later
approv
new
era
antivir
treatment
develop
began
de
clercq
li
viral
replic
cycl
involv
usag
host
cell
biochem
machineri
antivir
drug
also
affect
function
host
pathway
result
great
risk
toxic
therefor
major
concern
antivir
drug
develop
identif
specif
target
increas
select
reduc
side
effect
limit
therapeut
use
antivir
drug
comparison
antibacteri
agent
dal
pozzo
thiri
earli
stateoftheart
review
articl
antivir
chemotherapi
veterinari
medicin
list
sever
drawback
low
antivir
drug
use
veterinari
medicin
includ
usag
restrict
singl
viru
specif
anim
speci
problem
high
spectrum
activ
low
cytotox
high
cost
develop
new
chemic
compound
absenc
rapid
diagnost
techniqu
allow
prompt
use
specif
antivir
agent
cours
acut
infect
rollinson
b
antivir
drug
use
anim
medicin
origin
develop
human
viral
infect
clinic
use
veterinari
medicin
widespread
common
nevertheless
sever
licens
human
antivir
agent
use
cascad
principl
treatment
anim
diseas
eg
acyclovir
idoxuridin
trifluridin
felin
ocular
infect
cat
thiri
et
al
current
licens
antivir
drug
veterinari
medicin
felin
interferonomega
whose
mechan
action
involv
combin
antivir
immunostimulatori
activ
de
clercq
li
bracklein
et
al
antivir
agent
interfer
synthesi
regul
viral
nucleic
acid
fig
act
nucleosid
analogu
block
elong
newli
synthet
dna
rna
chain
antivir
agent
use
veterinari
medicin
act
neuraminidas
oseltamivir
amino
acid
llysin
inhibitor
novel
treatment
option
small
inhibitori
rna
also
investig
dal
pozzo
thiri
syke
recent
year
use
antivir
agent
veterinari
medicin
becom
favour
grow
interest
research
partial
due
success
outcom
antivir
therapi
human
diseas
partial
due
advanc
intern
veterinari
medicin
develop
novel
sophist
diagnost
treatment
protocol
addit
current
measur
control
viral
infect
vaccin
remov
infect
anim
breed
stock
cull
mani
limit
therefor
antivir
agent
repres
promis
altern
treatment
viral
diseas
veterinari
medicin
dal
pozzo
thiri
one
common
approach
antivir
drug
discoveri
ration
drug
design
base
understand
structur
function
target
molecul
compris
three
step
drug
design
identif
receptor
enzym
relev
diseas
drug
develop
discoveri
structur
function
receptor
enzym
interest
use
inform
step
order
design
drug
molecul
would
interact
receptor
enzym
therapeut
benefici
way
best
known
exampl
approach
azidothymidin
azt
use
treatment
human
immunodefici
viru
hiv
act
inhibit
hiv
revers
transcript
interestingli
origin
develop
target
revers
transcript
avian
retrovirus
may
caus
cancer
later
success
appli
hiv
well
olivero
wide
use
approach
highthroughput
screen
ht
method
enabl
valid
number
biolog
modul
chosen
set
defin
target
yield
rich
data
set
short
span
time
combin
expertis
liquid
handl
robot
autom
multiplatform
plate
read
highcont
imag
number
thu
emerg
activ
hit
normal
around
total
number
potenti
biolog
modul
screen
step
ht
pipelin
summar
follow
sampl
prepar
sampl
handl
readout
data
acquisit
common
ht
method
targetedselect
screen
divers
highcont
screen
rnai
screen
et
al
target
select
screen
base
identif
compound
select
inhibit
bind
specif
protein
interest
crystal
structur
protein
interest
known
usual
done
silico
threedimension
model
ligand
protein
interest
known
softwar
search
librari
compound
similar
characterist
bind
properti
exampl
approach
includ
identif
compound
hiv
filovirus
poxvirus
arenavirus
etc
marriott
et
al
anoth
commonli
use
screen
method
divers
screen
base
identif
compound
inhibit
viral
replic
pathogenesi
level
approach
involv
much
broader
target
base
instead
focus
screen
one
specif
protein
interest
appli
identif
candid
smallmolecul
inhibitor
dengu
viru
yellow
fever
viru
new
world
arenavirus
valler
green
highcont
screen
hc
subclass
divers
screen
method
develop
upon
autom
cellular
imag
analysi
techniqu
allow
imag
multipl
cell
time
measur
multipl
paramet
shape
textur
stain
local
intens
total
number
cell
size
nucleu
percentag
virusposit
cell
brodin
christoph
anoth
type
screen
antivir
drug
discoveri
rnai
screen
sirna
incorpor
rnainduc
silenc
complex
bind
target
mrna
therebi
induc
degrad
mrna
thu
prevent
translat
protein
shrna
hand
silenc
protein
form
short
hairpin
loop
fold
back
upon
genomewid
rnai
screen
use
studi
pathogenesi
hiv
influenza
viru
west
nile
viru
ebola
viru
etc
hirsch
addit
abovement
method
recent
advanc
genom
bioinformat
associ
technolog
offer
new
opportun
antivir
drug
discoveri
comput
method
enabl
construct
databas
contain
inform
relat
biolog
function
chemic
structur
biolog
activ
mani
properti
potenti
antivir
compound
contribut
identif
new
lead
bioactiv
speci
prichard
vidarabin
adenin
first
antivir
agent
licens
system
treatment
herp
viral
infect
human
fenner
et
al
adenosin
analogu
convert
cellular
enzym
activ
intracellular
deriv
vidarabin
triphosph
obtain
triphosph
form
act
competit
inhibitor
viral
host
dna
polymeras
viral
enzym
much
suscept
drug
host
cell
syke
schaechter
howev
independ
viral
thymidin
kinasemedi
phosphoryl
result
greater
host
cell
toxic
syke
use
topic
treatment
felin
herp
kerat
albeit
vitro
studi
shown
less
potent
felin
herpesvirus
trifluridin
idoxuridin
nasiss
vitro
activ
also
demonstr
felin
end
equin
rhinopneumon
ayisi
et
al
five
six
time
daili
administr
ophthalm
ointment
report
well
toler
cat
effect
treatment
felin
keratoconjunct
sicca
also
report
effect
idoxuridineresist
strain
syke
stile
acyclovir
acycloguanosin
acycl
analogu
purin
nucleosid
deoxyguanosin
wide
use
treat
herpesviru
famili
infect
syke
papich
perazella
shirali
activ
involv
phosphoryl
drug
firstli
virusencod
thymidin
kinas
enzym
monophosph
form
follow
phosphoryl
triphosph
host
cell
enzym
syke
papich
acyclovir
triphosph
better
substrat
viral
host
dna
polymeras
result
concentr
infect
cell
due
lack
group
drug
inhibit
viral
dna
polymeras
enzym
upon
incorpor
dna
chain
elong
disabl
syke
papich
salvaggio
gnann
henc
therapeut
mostli
use
treat
dna
viru
infect
particular
herp
simplex
viru
type
varicellazost
viru
salvaggio
gnann
anim
medicin
primarili
use
felin
infect
effici
human
viru
vitro
relat
low
oral
bioavail
cat
magg
clark
gaskel
et
al
nasiss
et
al
acyclovir
prodrug
valacyclovir
show
better
pharmacokinet
properti
term
enhanc
bioavail
result
faster
absorpt
oral
administr
upon
get
rapidli
metabol
acyclovir
acyclovir
entecavir
abil
block
nucleic
acid
synthesi
fig
howev
administr
valacyclovir
well
subsequ
increas
plasma
acyclovir
concentr
associ
advers
effect
nephrotox
myelosuppress
renal
hepat
necrosi
yet
effect
infect
nasiss
et
al
find
suggest
system
administr
neither
acyclovir
valacyclovir
recommend
treatment
herpesviru
infect
cat
ganciclovir
anoth
purin
nucleosid
analogu
resembl
acyclovir
wide
use
treat
cytomegaloviru
infect
human
medicin
shown
effect
vitro
unfortun
lack
data
efficaci
safeti
anim
syke
hand
topic
acyclovir
treatment
shown
effect
conjunct
kerat
appli
least
time
day
produc
toxic
effect
william
et
al
apart
cat
exist
studi
provid
data
acyclovir
treatment
hors
intraven
administr
result
halflif
contrari
low
oral
absorpt
william
et
al
rivier
papich
therefor
suggest
iv
treatment
could
administ
twice
daili
equin
rivier
papich
bird
oral
treatment
mgkg
acyclovir
everi
h
shown
minimum
dose
necessari
maintain
concentr
exhibit
antivir
effect
pheasant
rush
et
al
studi
dog
report
oral
absorpt
acyclovir
becom
satur
high
dose
de
miranda
et
al
penciclovir
guanosin
analogu
resembl
acyclovir
structur
mechan
action
antivir
activ
spectrum
compar
acyclovir
penciclovirtriphosph
accumul
virusinfect
cell
much
higher
concentr
longer
halflif
time
longer
acyclovir
salvaggio
gnann
gill
wood
howev
less
potent
acyclovir
triphosph
exhibit
lower
affin
viral
dna
polymeras
enzym
would
allow
lower
less
frequent
dosag
clinic
use
vitro
studi
proven
efficaci
viru
hepat
b
viru
dannaoui
et
al
shaw
et
al
korba
boyd
penciclovir
poor
oral
bioavail
famciclovir
develop
oral
formul
salvaggio
gnann
use
penciclovir
describ
along
famciclovir
famciclovir
diacetyl
ester
oral
prodrug
acyclovir
improv
bioavail
follow
oral
administr
get
rapidli
convert
activ
metabolit
penciclovir
dideacetyl
oxid
howev
pharmacokinet
penciclovir
famciclovir
cat
appear
nonlinear
satur
absorpt
variabl
compar
speci
support
observ
administr
dose
famciclovir
cat
speci
result
much
lower
plasma
concentr
longer
time
requir
reach
peak
plasma
concentr
cat
thomasi
et
al
thu
limit
famciclovir
metabol
stem
defici
hepat
aldehyd
oxidas
enzym
cat
convert
famciclovir
activ
form
dick
et
al
even
though
famciclovir
administ
high
oral
dose
develop
adequ
plasma
concentr
cat
seem
well
toler
success
treatment
conjunct
thomasi
et
al
malik
et
al
thomasi
et
al
due
satur
metabol
oral
administr
mg
famciclovirkg
cat
result
equival
serum
tear
penciclovir
concentr
impli
mgkg
equal
effect
higher
dose
thomasi
et
al
rat
dog
famciclovir
absorpt
metabol
appear
similar
previous
report
peopl
despit
observ
slower
convers
famciclovir
penciclovir
speci
filer
et
al
first
describ
witkowski
et
al
ribavirin
triazol
nucleosid
analogu
inhibit
replic
dna
rna
virus
interf
viral
mrna
synthesi
witkowski
et
al
activ
wide
rang
virus
includ
adenovirus
arenavirus
bunyavirus
herpesvirus
orthomyxovirus
paramyxovirus
picornavirus
poxvirus
retrovirus
rhabdovirus
rotavirus
strongest
effect
exhibit
influenza
virus
combin
interferon
hepat
c
viru
dolin
gustafson
te
et
al
sever
possibl
mechan
action
firstli
ribavirin
monophosph
gener
adenosin
kinasemedi
phosphoryl
indirectli
inhibit
synthesi
guanin
nucleotid
phosphoryl
triphosph
form
competit
inhibit
bind
atp
gtp
rna
polymeras
rivier
papich
oral
administ
ribavirin
shown
worsen
condit
cat
experiment
infect
caliciviru
toxic
effect
mainli
result
druginduc
thrombocytopenia
includ
depress
red
white
blood
cell
increas
alanin
aminotransferas
activ
icteru
bodi
weight
loss
howev
observ
clinic
symptom
withdrew
within
one
week
treatment
discontinu
rivier
papich
povey
interestingli
side
effect
observ
dog
treat
week
mgkg
drug
canonico
kitten
experiment
infect
felin
infecti
periton
viru
fipv
treatment
neither
free
liposom
ribavirin
improv
surviv
rate
similarli
anim
infect
caliciviru
result
intrins
toxic
rivier
papich
weiss
et
al
activ
ribavirin
also
demonstr
bovin
viral
diarrhoea
viru
bovin
herp
parrot
bornaviru
cell
cultur
model
glotov
et
al
musser
et
al
antivir
activ
benzimidazol
nucleosid
first
report
tamm
folker
cowork
design
benzimidazol
drb
variou
biolog
activ
includ
antivir
activ
rna
dna
virus
antivir
activ
drb
via
inhibit
cellular
rna
polymeras
ii
thu
inhibit
viral
cellular
rna
synthesi
migawa
et
al
porcari
et
al
chen
et
al
townsend
et
al
pharmaceut
chemistri
heterocycl
compound
particularli
benzenefus
great
import
class
benzenefus
compound
benzimidazol
deriv
known
wide
varieti
biolog
activ
biolog
activ
compound
vitamin
albendazol
mebendazol
thiabendazol
contain
benzimidazol
nucleu
structur
fig
shaharyar
et
al
relationship
sar
studi
show
due
chang
group
basic
structur
benzimidazol
display
wide
array
biolog
activ
includ
analges
antibacteri
antifung
anticanc
antivir
alaqeel
moreov
rang
structur
vari
nonnucleosid
inhibitor
nni
hcv
polymeras
share
benzimidazol
pharmacophor
report
among
class
compound
oral
activ
benzimidazol
deriv
phase
ii
clinic
trial
stage
japan
tan
et
al
tomei
et
al
current
number
benzimidazol
deriv
avail
market
omeprazol
rabeprazol
use
gastric
ulcer
telmisartan
candesartan
hypertens
astemizol
mizolastin
allerg
rhiniti
albendazol
oxibendazol
mebendazol
parasitosi
wang
et
al
benzimidazol
readili
interact
biopolym
live
system
due
fact
bioisoster
cellular
nucleotid
et
al
arildon
antivir
drug
phenoxyl
class
activ
dna
rna
virus
kuhrt
et
al
primarili
suggest
use
broadspectrum
antivir
agent
rel
less
toxic
drug
inhibit
viral
replic
lower
concentr
kim
et
al
sar
studi
demonstr
omiss
lipophil
substitu
arildon
diminish
antivir
activ
mcsharri
et
al
arildon
fig
inhibit
replic
enteroviru
particularli
polioviru
via
interact
viral
capsid
henc
block
viral
uncoat
nikolaevaglomb
galabov
vitro
studi
provid
evid
direct
interact
arildon
polioviru
capsid
stabil
virion
heat
alkalin
treatment
result
loss
capsid
polypeptid
block
releas
viral
rna
fox
et
al
uncoat
inhibit
action
arildon
lower
dose
block
replic
herp
viru
earlier
stage
polymeras
arildon
administ
solut
dimethyl
sulphoxid
dmso
due
poor
solubl
water
solvent
properti
dmso
may
augment
antivir
action
hutchinson
anim
model
experi
abil
arildon
block
virion
uncoat
properti
prevent
paralysi
death
studi
mice
intracerebr
infect
higher
dose
polioviru
strain
mef
moreov
ip
administr
arildon
suspend
gum
tragacanth
success
protect
anim
paralysi
death
dosedepend
fashion
minim
inhibitori
dose
mgkg
mckinlay
et
al
arildon
first
capsid
inhibitor
demonstr
vitro
inhibit
polioviru
replic
prevent
paralysi
death
poliovirusinfect
mice
compound
better
bioactiv
show
potenc
oral
mous
model
even
administ
day
intracerebr
infect
mckinlay
et
al
compound
consist
carbonphosphor
bond
rare
natur
consid
nonexist
till
recent
phosphonoacet
acid
paa
first
synthes
antivir
activ
discov
almost
year
later
shipkowitz
et
al
discoveri
paa
fig
antivir
drug
gave
rise
intens
research
biolog
activ
demonstr
paa
deriv
abil
inhibit
replic
number
virus
immunodefici
hepat
herp
virus
anim
studi
shown
paa
activ
herp
kerat
rabbit
herp
dermat
mice
paa
deriv
analogu
antimetabolit
pyrophosph
action
herp
virus
especi
viru
cmv
hsv
inhibit
dna
polymeras
import
herp
viru
replic
alimbarova
et
al
overbi
et
al
addit
depict
studi
polymeras
activ
inhibit
lyse
cultur
infect
cell
paa
without
affect
enzym
normal
cell
polymeras
normal
infect
cell
highli
purifi
investig
verifi
differenti
sensit
toward
paa
mao
et
al
amycolatopsi
rifamycinica
first
soil
bacteria
provid
rifamycin
consid
bacteri
sourc
rifamycin
till
discoveri
salinispora
group
although
sever
rifamycin
isol
bacteria
wide
use
deriv
rifampicin
rifampin
semisynthet
rifamycin
rifamycin
prefer
cross
mammalian
tissu
cell
membran
easili
bhattacharje
result
rifamycinsv
deriv
deem
first
line
treatment
intracellular
pathogen
demonstr
inhibitori
action
variou
biolog
system
among
antibacteri
agent
deriv
act
inhibit
bacteri
dnadepend
rna
polymeras
furthermor
rifampin
inhibit
poxviru
replic
vitro
via
mechan
inhibit
dnadepend
rna
polymeras
vitro
screen
select
inhibit
rnadepend
dna
polymeras
revers
transcriptas
number
deriv
reveal
certain
deriv
prevent
focu
format
rna
tumour
virus
szabo
et
al
rifamycin
deriv
also
found
act
type
ii
dna
topoisomeras
besid
phylogenet
studi
show
viral
type
ii
dna
topoisomeras
bacteri
counterpart
similar
indic
antibacteri
topoisomeras
inhibitor
act
african
swine
fever
asfv
replic
fact
fluoroquinolon
class
synthet
antibacteri
drug
shown
inhibit
asfv
replic
interact
type
ii
topoisomeras
zakaryan
revilla
rifampicin
rifapentin
rifabutin
fig
semisynthet
watersolubl
deriv
sv
use
therapi
differ
gramposit
gramneg
bacteri
strain
includ
methicillinresist
staphylococcu
aureu
mrsa
mycobacteria
mycobacterium
bovi
mycobacterium
tuberculosi
leprosi
legionella
also
abl
prevent
viral
infect
eg
influenza
czerwonka
et
al
antivir
potenti
antibacteri
drug
studi
variou
drug
minocyclin
among
well
investig
action
number
ailment
synthet
secondgener
tetracyclin
deriv
immunomodulatori
antiinflammatori
action
wide
use
treatment
acn
rheumatoid
arthriti
uti
potenti
antivir
action
minocyclin
human
immunodefici
viru
japanes
enceph
viru
west
nile
viru
report
also
found
promis
reduc
dengu
viru
infect
prompt
action
four
serotyp
viru
minocyclin
gener
diminish
viral
rna
synthesi
intracellular
viral
protein
synthesi
thu
infecti
viru
product
also
found
decreas
phosphoryl
associ
intensifi
pathogenesi
organ
damag
dengu
viru
infect
leela
et
al
furthermor
quinolon
show
antivir
activ
toward
hiv
hepat
c
viru
hcv
addit
antibacteri
anticanc
activ
particularli
antimalari
drug
chloroquin
amodiaquin
display
activ
virus
like
dengu
viru
west
nile
viru
ebola
viru
interf
viral
entri
replic
savoia
hand
compound
teicoplanin
isol
actinobacteria
member
actinoplan
teichomyceticu
ferment
product
exert
bactericid
action
inhibit
bacteri
cell
wall
biosynthesi
semisynthet
glycopeptid
teicoplanin
show
signific
inhibitori
activ
ebola
envelop
pseudotyp
virus
vero
cell
use
clinic
besid
teicoplanin
glycopeptid
antibiot
includ
dalbavancin
oritavancin
telavancin
vancomycin
inhibitori
action
entri
ebola
viru
sarscov
merscov
transcript
replicationcompet
viruslik
particl
regard
teicoplanin
antivir
activ
variou
studi
report
action
hiv
hepat
c
viru
flavivirus
coronavirus
respiratori
syncyti
viru
influenza
viru
colson
raoult
world
benefit
phenomen
discoveri
penicillin
alexand
fleme
develop
chain
florey
heatley
abraham
oxford
similarli
invent
import
streptomycet
product
waksman
woodruff
schatz
lechevali
rutger
univers
result
select
action
antibiot
pathogen
bacteria
fungi
ever
sinc
invent
penicillin
microb
play
signific
role
discoveri
newer
natur
productbas
drug
current
activ
compound
microbi
origin
includ
antimicrobi
antivir
cytotox
immunosuppress
compound
made
fungi
filament
bacteria
actinomycet
avail
demain
cyclosporin
fungusderiv
potent
immunosuppress
act
inhibit
cyclophilin
found
antivir
activ
nevertheless
immunosuppress
calcineurinrel
side
effect
made
imposs
use
antivir
agent
therefor
continu
search
structur
relat
cyclosporin
analogu
minim
immunosuppress
activ
strong
cyclophilin
inhibitori
action
result
deriv
nim
contrari
nim
time
less
immunosuppress
activ
cyclosporin
lesser
toxic
profil
demonstr
possess
antihiv
hcv
activ
nim
pass
evalu
phase
trial
treatment
hcv
butler
even
though
major
natur
product
produc
terrestri
environ
marin
organ
also
contribut
quit
larg
number
bioactiv
compound
bioactiv
compound
isol
marin
microb
variou
compound
anticanc
antibacteri
antivir
immunomodulatori
proteaseinhibit
activ
isol
marin
cyanobacteria
market
marin
product
includ
cytarabin
cytosar
nonhodgkin
lymphoma
antivir
vidarabin
viraa
ziconotid
prialt
trabectedin
yond
demain
histori
herbal
drug
use
widespread
develop
develop
countri
still
util
sever
reason
fewer
side
effect
rel
less
expens
patient
toler
accept
due
long
histori
use
vermani
garg
veregen
polyphenon
e
ointment
green
tea
leaf
extract
mixtur
catechin
first
herbal
remedi
obtain
fda
approv
treat
genit
wart
addit
perenni
herb
glycyrrhiza
glabra
use
year
japan
treatment
hepat
dri
process
root
licoric
uniqu
odour
sweet
tast
variou
studi
investig
pharmacolog
activ
licoric
viral
hepat
random
control
trial
conduct
glycyrrhiza
glabra
deriv
compound
glycyrrhizin
deriv
demonstr
diminish
hepatocellular
damag
chronic
hepat
b
c
fior
et
al
herb
caesalpinia
pulcherrima
swartz
leguminosa
common
medicin
plant
taiwan
flower
contain
number
metabolit
like
lupeol
lupeol
acet
myricetin
quercetin
rutin
quercetin
report
activ
bacteria
fungi
virus
human
immunodefici
viru
hiv
polioviru
herp
simplex
viru
hsv
indic
potenti
antibiot
furthermor
rutin
also
state
inhibit
replic
parasit
bacteria
fungi
virus
rotaviru
hsv
chiang
et
al
hand
china
taiwan
ocimum
basilicum
wide
use
tradit
number
infect
number
compound
reportedli
found
ocimum
basilicum
includ
monoterpenoid
carvon
cineol
fenchon
geraniol
linalool
myrcen
thujon
sesquiterpenoid
caryophyllen
farnesol
triterpenoid
ursol
acid
flavonoid
apigenin
particular
ursol
acid
shown
inhibitori
activ
herp
simplex
viru
hsv
human
immunodefici
viru
hiv
well
tumour
growth
chiang
et
al
drug
repurpos
drug
reposit
method
assign
new
medic
indic
exist
drug
reposit
drug
might
current
market
medic
withdrawn
due
advers
effect
prove
less
efficaci
matter
fact
drug
reposit
emerg
result
benefici
side
effect
serendip
howev
current
effort
attain
repurpos
accomplish
systemat
way
naveja
et
al
nowaday
problem
antimicrobi
drug
resist
pose
grow
threat
global
public
health
demand
newer
reposit
drug
regard
util
alreadi
fdaapprov
drug
anoth
indic
entiti
use
treat
new
indic
without
structur
modif
compound
hand
though
dose
formul
could
modifi
savoia
klug
et
al
case
ebola
viru
outbreak
west
africa
reach
scale
ever
seen
histori
greatest
public
health
emerg
antibodybas
therapi
prove
effect
macaqu
model
use
treat
patient
howev
suppli
drug
quit
limit
therefor
drug
repurpos
best
option
come
old
drug
new
indic
speed
discoveri
develop
antiebola
viru
drug
treatment
patient
ebola
viru
infect
result
initi
drug
repurpos
screen
subsequ
provid
approv
drug
ebola
viruslik
particl
entryblock
activ
includ
macrolid
antibiot
azithromycin
clarithromycin
block
bacteri
protein
synthesi
kouznetsova
et
al
final
six
antibiot
inhibit
ebola
viru
infect
azithromycin
erythromycin
spiramycin
dirithromycin
maduramicin
clarithromycin
select
antiebola
activ
fdaapprov
drug
veljkov
et
al
herbal
therapi
zika
viru
infect
howev
recent
two
antivir
agent
approv
fda
zika
viru
infect
cheng
et
al
import
design
develop
therapeut
approach
overcom
zika
viru
infect
special
focu
drug
target
viru
helicas
protein
nucleosid
inhibitor
protein
small
molecul
methyltransferas
inhibitor
repurpos
drug
repurpos
drug
chloroquin
azithromycin
niclosamid
use
treatment
zika
viru
infect
munjal
et
al
new
studi
reveal
alzheim
drug
may
moder
zika
virusmedi
neuron
damag
alzheim
diseas
drug
overstimul
nmethyldaspart
receptor
nmdar
lead
damag
neuron
death
interlink
zika
viru
infect
therefor
block
nmdar
channel
memantin
andor
antagonist
help
lessen
neuron
damag
associ
zika
viru
infect
act
preapprov
drug
food
drug
author
fda
need
clinic
trial
sirohi
kuhn
modif
specif
nonspecif
immun
respons
promis
intervent
ongo
viral
infect
suitabl
immunotherapi
chronic
viral
infect
hegd
et
al
first
exampl
monoclon
antibodi
specif
one
one
antigen
one
epitop
fibroblast
neuroblastoma
cell
monoclon
antibodi
specif
nucleoprotein
nonstructur
protein
nucleocapsid
shown
inhibit
rabi
viru
dosedepend
way
impair
transcript
genom
neutral
newli
translat
protein
lafon
lafag
addit
anoth
studi
found
monospecif
antibodi
rabi
viru
nucleoprotein
recogn
lyssavirusspecif
antigen
inou
et
al
monospecif
antibodi
shown
effect
noncapsid
protein
polioviru
pasamont
et
al
variou
livestock
diseas
rotavir
diarrhoea
bluetongu
classic
swine
fever
hendra
nipah
viral
infect
deb
et
al
neutral
antibodi
mediat
differ
mechan
destabil
virion
structur
aggreg
virion
inhibit
virion
attach
target
cell
inhibit
virion
lipid
membran
fusion
membran
host
cell
inhibit
entri
genom
nonenvelop
virus
cell
cytoplasm
inhibit
function
virion
core
signal
transduc
antibodi
read
dimmock
anoth
therapeut
strategi
infecti
viral
diseas
recombin
antibodi
unlik
monoclon
antibodi
need
hybridoma
anim
product
process
synthet
antibodi
code
gene
deliv
high
reproduc
specif
scalabl
echko
dozier
exampl
includ
avian
antibodi
infecti
bursal
diseas
viru
protect
viral
infect
chicken
zhang
et
al
porcin
circoviru
type
yang
et
al
protein
classic
swine
fever
viru
chen
et
al
capsid
protein
bovin
immunodefici
viru
bhatia
et
al
antivir
drug
test
variou
viral
diseas
anim
antivir
therapi
develop
number
rna
viral
infect
livestock
first
among
footandmouth
diseas
fmd
involv
vaccin
contain
inactiv
wholeviru
antigen
howev
sinc
vaccin
anim
differenti
infect
one
vaccin
use
elimin
fmd
outbreak
previous
diseasefre
countri
henc
interferon
ifn
emerg
anoth
treatment
agent
includ
use
individu
synergist
describ
sever
target
possess
antivir
properti
indoleamin
induc
nitric
oxid
synthas
mora
et
al
one
widespread
diseas
domest
livestock
caus
anoth
rna
viral
infect
bluetongu
viru
btv
aminothiophenecarboxyl
acid
deriv
name
compound
deriv
compound
identifi
virostat
molecul
btv
exert
effect
inhibit
btvinduc
apoptosi
via
inhibit
activ
inhibit
host
autophagi
activ
gu
et
al
furthermor
felin
herp
viru
type
common
caus
variou
diseas
cat
ocular
surfac
diseas
respiratori
diseas
dermat
potenti
intraocular
diseas
number
antivir
agent
describ
viru
effect
antivir
therapi
one
target
viral
protein
involv
dna
synthesi
mani
use
close
relat
human
herp
simplex
viru
type
exampl
nucleosid
nucleotid
analogu
report
topic
administr
vidarabin
affect
dna
polymeras
subsequ
disrupt
dna
synthesi
trifluridin
act
fluorin
nucleosid
analogu
thymidin
cidofovir
cytosin
analogu
act
two
hostmedi
phosphoryl
step
thomasi
magg
purin
analogu
oral
prodrug
also
describ
well
antivir
drug
foscarnet
inhibit
pyrophosph
bind
site
viral
dna
polymeras
numer
novel
compound
investig
includ
sirna
target
glycoprotein
gd
alon
jointli
dna
polymeras
gene
wilk
kania
conclud
equin
herpesviru
type
infect
caus
outbreak
respiratori
variou
neurolog
diseas
hors
acyclovir
valacyclovir
common
drug
also
ifn
target
ifngr
complex
key
mediat
virusspecif
cellular
immun
poelaert
et
al
felin
immunodefici
viru
fiv
complex
lentiviru
caus
immunodefici
diseas
cat
manifest
bodi
inabl
develop
normal
immun
respons
retroviru
insert
copi
genet
materi
dna
host
cell
replic
commonli
use
antiretrovir
drug
revers
transcriptas
inhibitor
rti
particular
one
act
nucleosid
analogu
similar
structur
intrins
nucleosid
therefor
block
enzymat
activ
bind
activ
centr
enzym
hartmann
et
al
first
among
zidovudin
azt
report
improv
immunolog
clinic
statu
fivinfect
cat
increas
qualiti
life
well
prolong
life
expect
shown
increas
ratio
natur
fivinfect
cat
act
inhibit
rt
also
cellular
polymeras
lead
bone
marrow
suppress
hartmann
anoth
drug
act
rti
stavudin
shown
activ
fiv
vitro
howev
mani
resist
strain
arisen
similarli
didanosin
lamivudin
shown
potenc
fiv
vitro
condit
schwartz
et
al
addit
combin
zidovudin
lamivudin
investig
result
synergist
antifiv
effect
cell
cultur
also
highdos
zidovudinelamivudin
combin
shown
protect
infect
treatment
initi
viru
inocul
arai
et
al
moreov
abovement
antivir
agent
also
effect
hiv
infect
interferon
ifn
multigen
famili
induc
cytokin
possess
antivir
activ
ifn
system
compris
cell
synthes
ifn
respons
extern
stimulu
viral
infect
cell
respond
ifn
establish
antivir
state
repres
earli
host
defenc
one
occur
prior
immun
respons
onset
ifn
classifi
produc
cell
respons
viru
infect
synthet
upon
antigen
mitogen
stimul
samuel
activ
report
number
felin
virus
includ
felin
caliciviru
fcv
act
stimul
downstream
gene
ribonucleas
l
rnase
l
degrad
singlestrand
viral
rna
also
felin
shown
reduc
upon
fcv
infect
report
posit
regul
ifn
signal
trigger
product
endogen
ifn
express
downstream
target
gene
liu
et
al
mention
anoth
felin
viru
report
ifn
therapeut
solut
fiv
best
known
among
recombin
first
interferon
compound
licens
use
veterinari
medicin
shown
significantli
increas
level
acut
phase
protein
app
et
al
also
report
antiinflammatori
properti
exert
via
leal
et
al
recombin
human
interferon
recombin
felin
interferon
omega
rfeifnomega
also
exhibit
antivir
effect
felin
herpesviru
fhv
vitro
set
evidenc
signific
reduct
plaqu
size
siebeck
et
al
interferon
also
show
therapeut
potenti
felin
leukaemia
viru
felv
recombin
felin
interferon
rfeifnomega
result
improv
clinic
sign
surviv
infect
cat
de
mari
et
al
idoxuridin
trifluridin
structur
similar
thymidin
analogu
inhibit
synthesi
dna
appli
treatment
felin
significantli
reduc
number
viral
plaqu
vitro
nasiss
et
al
idoxuridin
also
exhibit
therapeut
potenti
equin
herpesviru
type
allevi
ocular
symptom
caus
infect
collinson
et
al
also
report
idoxuridin
concentr
trifluridin
limit
viral
replic
kill
viru
plummer
et
al
antivir
drug
vaccin
power
tool
combat
viral
diseas
howev
mostli
select
target
singl
viru
known
one
bug
principl
contrari
broadspectrum
antivir
bsa
cover
multipl
virus
genotyp
therefor
reduc
likelihood
resist
develop
henc
reduc
complex
treatment
ensur
manag
new
drugresist
viral
strain
firstlin
treatment
prophylaxi
acut
infect
well
coinfect
zhu
et
al
virus
hepat
c
directact
antivir
agent
daa
develop
past
year
act
proteas
inhibitor
inhibitor
inhibitor
ensur
effici
toler
safe
interferonfre
oral
therapi
da
pandya
furthermor
develop
antivir
agent
focu
viral
factor
potenti
target
inhibit
also
host
factor
well
cellular
receptor
adhes
molecul
cyclophilin
microrna
therefor
effort
put
combin
viral
host
inhibitor
eventu
lead
interferonfre
therapi
consist
clear
infect
bryanmarrugo
et
al
perspect
use
antivir
drug
livestock
anim
envisag
mass
treatment
control
diseas
larg
scale
wherea
treatment
companion
anim
favour
individu
approach
main
prerequisit
success
veterinari
antivir
chemotherapi
better
understand
viral
infect
pathogenesi
well
develop
sophist
mean
drug
deliveri
mainli
focu
target
approach
aim
specif
molecular
target
narrow
nich
allow
better
specif
less
side
effect
antivir
agent
advanc
field
molecular
biolog
particular
comput
approach
would
contribut
develop
new
gener
antivir
therapi
would
import
control
variou
kind
anim
diseas
use
anim
model
virus
human
veterinari
import
still
abundantli
use
develop
therapeut
agent
howev
current
interest
variou
virus
lead
multipl
drug
resist
due
use
higherdosag
therapi
approach
differ
companion
anim
singl
method
prefer
largescal
livestock
mass
treatment
therapi
use
antivir
drug
natur
well
herbal
product
character
novel
optimist
approach
still
worthi
notic
therapi
lead
multipl
drug
resist
overcom
futur
